Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label infusion dose optimization study of ABP-700 in healthy adults
NL-OMON26835Phase 1Unknown
- Sponsor
- The Medicines Company
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of moxetomidate, sponsored by The Medicines Company. Primary endpoint: Safety and tolerability of IV infusion doses and infusion methodologies of ABP-700. Status: unknown.
02
Drugs
moxetomidate
Beyond the preview
Go deeper on NL-OMON26835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26835.